Pipeline

VRS-859

Therapeutic Protein/Peptide Component:		Indication(s):
Exenatide (glucagon-like peptide-1 analog)		Type 2 diabetes

Development Status:
Phase 1a clinical trials in patients with T2DM (currently enrolling)